Navigation Links
Statins Lower Blood Marker for Prostate Cancer
Date:10/30/2008

But it's not clear if the cholesterol-lowering drugs protect against the disease

THURSDAY, Oct. 30 (HealthDay News) -- A new study shows that men who take cholesterol-lowering drugs called statins have lower blood levels of prostate-specific antigen (PSA), a biomarker for prostate cancer risk.

That drop in PSA levels doesn't necessarily mean the drugs protect against disease however, researchers say.

But it's possible that statins may offer some protection against the disease, said Dr. Robert Hamilton, one author of the report in the Oct. 28 issue of the Journal of the National Cancer Institute. He worked on the study while a research fellow at Duke University; he is now a urology resident at the University of Toronto.

"The reduction in PSA was in proportion to the dose of statins that were taken and to the reduction of cholesterol levels," Hamilton said, indicators of a possible protective effect.

The study was done because of "encouraging recent data" from four previous studies showing an association between statin therapy and reduced PSA levels, and a reduced risk of advanced prostate cancer, he said.

The study followed 1,214 men who were prescribed statins between 1990 and 2006 at the Durham Veterans Affairs Medical Center in North Carolina. PSA levels declined by about 4 percent after statin therapy was started, with the greatest reductions seen in men who took the largest doses of statins and had the largest drops in blood cholesterol levels.

The results parallel those of a study reported in 2005 by a group led by Dr. Dov Kadmon, a professor of urology at the Baylor College of Medicine.

"Our study was the first to show a relationship between PSA levels and either lowering of cholesterol or treatment with statins," Kadmon said. "We could not distinguish whether lowering cholesterol or statin treatment was responsible, because our study was not designed to show that."

Kadmon and his colleagues followed 100 commercial airline pilots, a group chosen because federal regulations require them to have regular medical exams. The five-year study showed that "pilots on statins had a 46 percent decrease in PSA levels, while the control group had a slow increase in PSA levels, which are known to go up with age," Kadmon said.

The study was too small and too short to tell whether statins might protect against prostate cancer, Kadmon said. "But we know that when men have higher PSA levels, there is a higher chance that they will be diagnosed with prostate cancer," he said. "It is worth looking into by conducting a larger study."

"There is no question that a large, randomized, controlled trial with a long follow-up would most likely answer the question," Hamilton said. "It would be an expensive, huge undertaking."

Why statins affect PSA levels is unclear, Hamilton said. "We have some idea of how statins interact with prostate biology," he said. "But we don't know the exact mechanism by which statins influence PSA."

The anti-inflammatory action of statins is one of the possible mechanisms, Hamilton said. "We need to learn more about prostate cancer and statins before we launch a huge study," he added.

More information

Statins and other drugs that lower cholesterol are described by the American Heart Association.



SOURCES: Robert Hamilton, M.D., urology resident, University of Toronto; Dov Kadmon, M.D., professor, urology, Baylor College of Medicine, Houston; Oct. 28, 2008, Journal of the National Cancer Institute


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Stopping Statins After Stroke Doubles Death Risk
2. Research to shed new light on how statins benefit heart patients
3. Statins reduce loss of function, keeping old lungs young - even in smokers
4. Better Prostate Cancer Survival for Men Taking Statins
5. Statins After Bypass Lower Stroke Risk
6. Latest Study Says Statins Dont Slow Alzheimers
7. New Gene-Based Therapy an Alternative to Vytorin and Statins in Heart Disease Prevention and Treatment
8. Tendon complications, though rare, linked to statins
9. Cholesterol-Lowering Statins Tied to Tendon Woes
10. Women are treated less frequently than men with statins, aspirin and beta-blockers
11. iGuard.org Presents New Data on Statins at FDA Workshop Demonstrating How Patient-Reported Information Can Enhance Drug Safety Knowledge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... choose a modern procedure that achieves results in a fraction of the time ... Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment with ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers of America ... a reputable physician in their area, announces the launch of a new and proprietary ... who are looking for reputable physicians to help them with back or neck pain ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
(Date:4/25/2017)... ... 2017 , ... Vetoquinol USA® , a world-class developer ... of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. ... level. , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the ... CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet in ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... PARIS , April 20, 2017 ... EyeCET platform, the first non-viral gene expression technology that ... in the eye to address a wide range of ... UK Medicines and Healthcare products Regulatory Agency (MHRA) to ... ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
Breaking Medicine Technology: